The European Medicines Agency (EMA) could approve a Pfizer/BioNTech Covid vaccine targeting two fast-spreading subvariants of the Omicron strain as early as the fall, a spokesperson for the regulator said on Wednesday.
“
The EMA expects to receive an application for the adapted BA.4/5 vaccine developed by Pfizer /BioNTech, which will be evaluated for potential rapid approval in the fall
,” a spokesperson told AFP. .